CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- 4 Grant or award Director acquired 57,000 shares (grant or award)
- 4 Grant or award Director acquired 57,000 shares (grant or award)
- 4 Open-market sale EVP, Chief Legal Officer sold 8,389 shares at an average $2.04 ($17,089)
- 4 Open-market sale EVP, Chief Technical Officer sold 19,040 shares at $2.04 ($38,784)
- 4 Open-market sale President and CEO sold 29,766 shares at $2.04 ($60,633)
- 4 Open-market sale SVP, CFO sold 7,918 shares at an average $2.04 ($16,131)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President and CEO sold 15,679 shares at $3.63 ($56,868)
- 4 Open-market sale SVP, GC & Secretary sold 4,221 shares at $3.63 ($15,310)
- 4 Open-market sale Chief Financial Officer sold 6,871 shares at $3.63 ($24,921)
- 4 Open-market sale EVP, Head of R&D sold 5,074 shares at $3.63 ($18,403)
- 4 Grant or award President and CEO acquired 324,711 shares (grant or award)
- 4 Grant or award EVP, Chief Technical Officer acquired 139,700 shares (grant or award)
- 4 Grant or award EVP, Head of R&D acquired 141,328 shares (grant or award)
- 4 Grant or award SVP, GC & Secretary acquired 155,375 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 2,485 shares at $5.46 ($13,568)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale EVP, Head of R&D sold 4,342 shares at an average $4.49 ($19,497)
- 4 Open-market sale President and CEO sold 15,591 shares at $4.49 ($70,004)
- 4 Open-market sale SVP, GC & Secretary sold 3,612 shares at $4.49 ($16,218)
Page 6 of 33 · 644 filings